Business Description
Cullinan Oncology Inc
NAICS : 541713
SIC : 2834
One Main Street, Suite 520, Cambridge, MA, USA, 02142
Description
Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 152.92 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | -1.84 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.5 | |||||
3-Year EPS without NRI Growth Rate | -7.1 | |||||
3-Year FCF Growth Rate | 5.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 71.12 | |||||
9-Day RSI | 62.64 | |||||
14-Day RSI | 60.13 | |||||
6-1 Month Momentum % | 1.29 | |||||
12-1 Month Momentum % | -50.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 18.68 | |||||
Quick Ratio | 18.68 | |||||
Cash Ratio | 18.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -57 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -17.56 | |||||
ROA % | -17.08 | |||||
ROIC % | -75.9 | |||||
ROC (Joel Greenblatt) % | -13932.1 | |||||
ROCE % | -22.97 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 4.14 | |||||
PS Ratio | 33.66 | |||||
PB Ratio | 1.58 | |||||
Price-to-Tangible-Book | 1.58 | |||||
EV-to-EBIT | -3.44 | |||||
EV-to-EBITDA | -3.44 | |||||
EV-to-Forward-Revenue | 1.27 | |||||
EV-to-FCF | -5.49 | |||||
Price-to-Net-Current-Asset-Value | 2.18 | |||||
Price-to-Net-Cash | 2.23 | |||||
Earnings Yield (Greenblatt) % | -29.07 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:CGEM
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -1.79 | ||
Beta | 0 | ||
Volatility % | 55.86 | ||
14-Day RSI | 60.13 | ||
14-Day ATR ($) | 0.769773 | ||
20-Day SMA ($) | 14.272 | ||
12-1 Month Momentum % | -50.65 | ||
52-Week Range ($) | 7.3 - 30.325 | ||
Shares Outstanding (Mil) | 44.78 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cullinan Oncology Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |